AU2003286726A8 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics - Google Patents

Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Info

Publication number
AU2003286726A8
AU2003286726A8 AU2003286726A AU2003286726A AU2003286726A8 AU 2003286726 A8 AU2003286726 A8 AU 2003286726A8 AU 2003286726 A AU2003286726 A AU 2003286726A AU 2003286726 A AU2003286726 A AU 2003286726A AU 2003286726 A8 AU2003286726 A8 AU 2003286726A8
Authority
AU
Australia
Prior art keywords
metabolomics
diagnosis
methods
drug discovery
disease treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286726A
Other versions
AU2003286726A1 (en
Inventor
Rima Kaddurah-Daouk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of AU2003286726A8 publication Critical patent/AU2003286726A8/en
Publication of AU2003286726A1 publication Critical patent/AU2003286726A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU2003286726A 2002-10-25 2003-10-27 Methods for drug discovery, disease treatment, and diagnosis using metabolomics Abandoned AU2003286726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42122602P 2002-10-25 2002-10-25
US60/421,226 2002-10-25
PCT/US2003/034172 WO2004038381A2 (en) 2002-10-25 2003-10-27 Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Publications (2)

Publication Number Publication Date
AU2003286726A8 true AU2003286726A8 (en) 2004-05-13
AU2003286726A1 AU2003286726A1 (en) 2004-05-13

Family

ID=32176684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286726A Abandoned AU2003286726A1 (en) 2002-10-25 2003-10-27 Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Country Status (2)

Country Link
AU (1) AU2003286726A1 (en)
WO (1) WO2004038381A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc Methods for drug discovery, disease treatment, and diagnosis using metabolomics
BRPI0613478B8 (en) * 2005-06-30 2021-07-27 Biocrates Life Sciences Ag device for quantitative analysis of a metabolite profile
US8637321B2 (en) 2005-10-24 2014-01-28 Duke University Lipidomics approaches for central nervous system disorders
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
WO2007127192A2 (en) * 2006-04-24 2007-11-08 Duke University Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8849577B2 (en) 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
US7728287B2 (en) 2007-03-01 2010-06-01 Lawrence Livermore National Security, Llc Imaging mass spectrometer with mass tags
MX2012000952A (en) * 2009-07-22 2012-02-28 Lilly Co Eli Method for predicting weight gain associated with a pharmaceutical therapy.
ES2455124T5 (en) 2010-05-05 2018-05-08 Zora Biosciences Oy Lipidomic biomarkers for atherosclerosis and heart disease
US9201080B2 (en) 2010-06-20 2015-12-01 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2014004539A1 (en) * 2012-06-26 2014-01-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Metabolomics in pneumonia and sepsis
CA2945165A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
CN113514559A (en) * 2020-04-09 2021-10-19 四川好医生攀西药业有限责任公司 Method for controlling quality of periplaneta americana ethanol extract

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376210B1 (en) * 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
US6677160B1 (en) * 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6566086B1 (en) * 2000-01-28 2003-05-20 Fal Diagnostics Diagnostic kit for detecting creatine levels
EP1285092A4 (en) * 2000-04-14 2003-07-16 Metabolon Inc Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2002004465A1 (en) * 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds

Also Published As

Publication number Publication date
WO2004038381A3 (en) 2004-07-01
AU2003286726A1 (en) 2004-05-13
WO2004038381A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
EP1285092A4 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2003301347A1 (en) Methods for monitoring treatment of disease
AU2003286726A8 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1804661A4 (en) Integrated disease diagnosis and treatment system
AU2003902503A0 (en) Medical Apparatus, Use and Methods
HK1079993A1 (en) Drugs for treating vascular diseases
GB0516702D0 (en) Membrane-permeant peptide complexes for medical imaging diagnostics, and pharmaceutical therapy
AU2003223172A1 (en) Use of the axl receptor for diagnosis and treatment of renal disease
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
AU2003210266A1 (en) Treatment, diagnosis and imaging of disease
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
AU2003223780A1 (en) Treatment for pompe disease
AU2003298719A8 (en) Treatment for sma disease
GB9909392D0 (en) Treatment, imaging and diagnosis of disease
AU2003277202A8 (en) Methods for diagnosing bone turnover disease
GB2441078B (en) Implantable network biosensor and system for diagnosis and therapy
EP1438431A4 (en) Methods for diagnosing and treating heart disease
GB0300428D0 (en) Medical treatment
EP1408808A4 (en) Methods for diagnosing and treating heart disease
PT1474415E (en) 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases
GB0128628D0 (en) Disease treatment
GB0215095D0 (en) Treatment, diagnosis and imaging of imaging of disease
GB0317586D0 (en) Treatment, diagnosis and imaging of disease
AU2003248679A1 (en) Treating disease using radium-225
TJ20010729A (en) Method of recovering bone structure after ablationsequestrum of the patients with chronic disease o steomyelitis of lower jaw.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase